Last Updated : March 18, 2024
Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Therapeutic Area: Hemophilia B
Draft recommendations posted for stakeholder feedback: March 21, 2024
End of feedback period: April 5, 2024
Draft Recommendation
Therapeutic Area: Crohn’s disease
Draft recommendations posted for stakeholder feedback: March 21, 2024
End of feedback period: April 05, 2024
Draft Recommendation
Therapeutic Area: Ulcerative Colitis
Draft recommendations posted for stakeholder feedback: March 21, 2024
End of feedback period: April 05, 2024
Draft Recommendation
Therapeutic Area: Alagille syndrome
Draft recommendations posted for stakeholder feedback: March 21, 2024
End of feedback period: April 5, 2024
Draft Recommendation
Therapeutic Area: Seizures associated with Tuberous Sclerosis Complex (TSC)
Draft recommendations posted for stakeholder feedback: March 21, 2024
End of feedback period: April 5, 2024
Draft Recommendation
Therapeutic Area: Dravet Syndrome (DS)
Draft recommendations posted for stakeholder feedback: March 21, 2024
End of feedback period: April 5, 2024
Draft Recommendation
Therapeutic Area: Lennox-Gastaut Syndrome (LGS)
Draft recommendations posted for stakeholder feedback: March 21, 2024
End of feedback period: April 5, 2024
Draft Recommendation
Therapeutic Area: Primary hypercholesterolemia
Draft recommendations posted for stakeholder feedback: March 21, 2024
End of feedback period: April 5, 2024
Draft Recommendation
Therapeutic Area: Primary hypercholesterolemia
Draft recommendations posted for stakeholder feedback: March 21, 2024
End of feedback period: April 5, 2024
Draft Recommendation